...Phase I for rheumatoid arthritis. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:750px;"> KT-474 from Kymera Therapeutics...
...family zinc finger 1 (IKAROS) (IKZF1) (LYF1)IRAK4 – Interleukin-1 receptor-associated kinase 4 Danielle Golovin PF-06650808 R835 Pfizer Inc. Rigel Pharmaceuticals Inc. Kymera Therapeutics...

...year, with Arvinas Inc .(NASDAQ:ARVN) unveiling the first clinical efficacy data for a protein degrader; Kymera Therapeutics...

...degrader ARV-471. Three targeted protein degradation companies —Kymera Therapeutics...

...protein degradation companies set to enter the clinic this year. Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), Kymera Therapeutics...

...degradation: cereblon, vHL and IAP.  Companies including Arvinas, Kymera Therapeutics...
...– von Hippel-Lindau tumor suppressor Karen Tkach Tuzman Arvinas Inc. Kymera Therapeutics...

...performance is in line with two other protein degradation companies that went public this summer: Kymera Therapeutics...

...Medical Products Administration), but resigned in March 2018 amid a vaccines manufacturing scandal (see “Thinking Beyond Bi”).Kymera Therapeutics...
...a new position. She joined the hematological malignancies company in 2017 as director of operations. Robin Sawka Kymera Therapeutics...

...upfront and most advanced partnered protein degradation asset to date, with Sanofi (Euronext:SAN; NASDAQ:SNY) paying Kymera Therapeutics...
...None issued Danielle Golovin Amphista Therapeutics Ltd. University of Dundee Advent Life Sciences Scottish Investment Bank Scottish Growth Scheme European Investment Fund BioMotiv Arvinas Inc. Kymera Therapeutics...

...BCIQ database (see “Preclinical IPOs Attracting Big Money”). Kymera Therapeutics...
...receptor 2IRAK4 – Interleukin-1 receptor-associated kinase 4 Paul Bonanos Kymera Therapeutics...

...once the deals are complete (see “Kidney Play Chinook Rounds Out Pipeline”).Kymera sets IPO termsIf Kymera Therapeutics...
...member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo Pharma Inc. Kymera Therapeutics Chinook...